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Abstract: We herein report a patient with advanced hepatitis B virus-related hepatocellular 
carcinoma (HCC) beyond the Milan criteria. He underwent orthotopic liver transplantation 
after successful HCC downstaging that satisfied the University of California, San Francisco 
criteria, using concurrent chemoradiation therapy with a combination of repeated hepatic 
arterial infusion chemotherapy (HAIC) and sorafenib. A 52-year-old male was diagnosed with 
advanced hepatitis B virus-related HCC beyond the Milan criteria. He underwent concurrent 
chemoradiation therapy (50 Gy with 20 fractions over 5 weeks with HAIC using 5-fluorouracil 
at a dose of 500 mg/day, which was administered during the first and fifth weeks of radiation 
therapy) as an initial treatment modality. This was followed by the combined use of HAIC 
using 5-fluorouracil (500 mg/m2 for 5 hours on days 1–3) and cisplatin (60 mg/m2 for 2 hours 
on day 2) every 4 weeks (twelve cycles) and sorafenib (from the third to the twelfth cycle of 
HAIC) to treat the remaining HCC. Because a remarkable decrease in the tumor burden that 
satisfied the University of California, San Francisco criteria was observed after these combination 
treatments, the patient underwent orthotopic liver transplantation with curative aim and survived 
for 11 months without evidence of HCC recurrence.
Keywords: hepatocellular carcinoma, liver transplantation, sorafenib, concurrent chemoradia-
tion, hepatic arterial infusion chemotherapy, downstaging
Introduction
Orthotopic liver transplantation (OLT) has long been the most appropriate treatment 
modality for patients with HCC combined with advanced cirrhosis, not only because the 
tumor can be removed, but because the cirrhotic liver, which is at risk for development 
of new lesions, can be replaced. However, OLT has been reserved for a specific 
population with early HCC, and the Milan criteria1 (single tumor up to 5 cm or up to 
three tumors, each no larger than 3 cm, without macrovascular invasion or extrahepatic 
spread) have been its selection criteria. These criteria predicted almost identical 
outcomes when compared with OLT performed in subjects without HCC.
However, recent studies have tried to expand the indication for OLT to overcome 
the donor shortage.2–5 First, some investigators have proposed more extended selection 
criteria, such as the University of California, San Francisco (UCSF) expanded criteria 
(solitary tumor of 6.5 cm in diameter, or three nodules with the largest diameter 
of 4.5 cm and a total tumor diameter of 8 cm)2 and the up-to-7 criteria (HCC with 
7 as the sum of the size [in cm] of the largest tumor and the number of tumors).3 
Furthermore, downstaging of HCC by decreasing the tumor size with locoregional 
therapies with or without systemic therapies to meet the acceptable criteria for OLT 
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has also been attempted in patients with HCC above the 
Milan criteria.4 Indeed, several meta-analyses have reported 
that the post-transplant 5-year survival rates for patients with 
downstaged tumors were slightly below or even identical to 
those achieved in patients with HCC initially meeting the 
Milan criteria.5
We herein report a patient who initially had advanced 
hepatitis B virus (HBV)-related HCC beyond the Milan 
criteria. He underwent OLT after successful downstaging 
of the HCC that satisfied the UCSF criteria using concur-
rent chemoradiation therapy (CCRT) with the combined use 
of twelve cycles of hepatic arterial infusion chemotherapy 
(HAIC) and sorafenib.
Case report
A 52-year-old male presented to our hospital in November 
2009 with a history of abdominal pain and weight loss that had 
been present for a few months. He had been first diagnosed 
as an HBV carrier 20 years previously. His baseline labora-
tory test results were as follows: platelet count, 220,000/µL; 
international normalized ratio, 0.95; serum albumin, 4.6 g/dL; 
aspartate aminotransferase, 61 IU/L; alanine aminotrans-
ferase, 44 IU/L; total bilirubin, 0.37 mg/dL; and alkaline 
phosphatase, 119 IU/L. Hepatitis B e antigen was positive, 
and the serum HBV DNA level was 1.60 × 106 IU/mL. The 
α-fetoprotein (AFP) level was 3690.65 IU/mL.
A computed tomography (CT) scan demonstrated find-
ings typical of liver cirrhosis, an approximately 14.5 cm 
hypervascular mass in the right lobe of the liver without 
invasion of the middle hepatic vein, and an enlarged lymph 
node in the right anterior cardiophrenic space suggestive of 
metastasis in the lymph node (Figure 1A and B). A huge 
liver mass with inner necrosis and intense peripheral fluoro-
deoxyglucose (FDG) uptake suggestive of high-grade HCC 
and borderline-size right cardiophrenic area also showed 
similar FDG uptake on positron emission tomography (PET) 
and CT. Finally, HCC was confirmed based on these typical 
radiological findings with elevated tumor markers.6
Because the initial tumor stage of the patient was T2N1M0 
(stage IVa) according to the modified American Joint Com-
mittee on Cancer/Union for International Cancer Control 
staging system in 2002,7 the HCC was not resectable. Thus, 
the patient received CCRT from October 2009 (50 Gy with 
20 fractions over 5 weeks with HAIC using 5-fluorouracil at 
a dose of 500 mg/day, which was administered during the 
first and fifth weeks of radiation therapy) via an implanted 
chemoport (Figure 2).8 One month after CCRT, the HCC 
decreased from 14.5 to 9.0 cm, and the metastatic lymph node 
in the right cardiophrenic area disappeared (partial response 
according to the modified Response Evaluation Criteria in 
Solid Tumors [RECIST]).9 In addition, the AFP level mark-
edly dropped from 3690.65 to 31.55 IU/mL.
Because an intrahepatic tumor was still viable, HAIC 
using 5-fluorouracil (500 mg/m2 for 5 hours on days 1–3) 
and cisplatin (60 mg/m2 for 2 hours on day 2) were addition-
ally administered and repeated every 4 weeks. After two 
cycles of HAIC following CCRT, a new 1.6 cm HCC lesion 
appeared. To prevent locoregional cancer progression and 
distant metastasis due to the potential resistance of HCC to 
HAIC, sorafenib (Nexavar; Bayer, Leverkusen, Germany) 
was additionally initiated in May 2010 (400 mg orally, twice 
daily), just after the completion of the second cycle of HAIC. 
The dose of sorafenib was reduced to 400 mg once daily 
because of grade 1 hand–foot syndrome (NCI CTCAE v3.0) 
after 9 weeks of sorafenib use.10 A total of twelve cycles of 
HAIC following CCRT were completed by November 2010. 
However, sorafenib was maintained for an additional 2 years 
until the end of March 2012 (Figure 2).
After the completion of 2 years of sorafenib monotherapy 
in March 2012, the size of the primary tumor had further 
decreased to 6.4 cm, and a suspicious HCC lesion that had 
developed after two cycles of HAIC had also disappeared 
(Figure 3A). In addition, a remarkable decrease in FDG 
uptake in the primary tumor was identified without visible 
distant metastasis on PET-CT (Figure 3B). The serum AFP 
level was maintained as normal, at 1.7 IU/mL. Although 
the treatment response was favorable, liver function was 
decompensated with a large amount of ascites and peripheral 
edema. At that time, the Model for End Stage Liver Disease 
score was 36.56, and the patient’s expected survival was less 
than 3 months.11 Thus, the patient underwent OLT from an 
unrelated living donor in April 2012 (31 months from initial 
anticancer treatment) to cure the remaining HCC meeting the 
UCSF criteria and decompensated liver cirrhosis. Grossly, 
the extracted liver showed mixed macro- and micronodular 
cirrhotic changes (Figure 4A). Microscopic examination 
Figure 1 Computed tomography demonstrated a cirrhotic liver with a 14.5 cm 
hepatocellular carcinoma (white arrow) in the right lobe (A) and an enlarged lymph 
node in the right anterior cardiophrenic area (black arrow, B).
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showed total necrosis of the HCC and fibrous capsule 
formation (Figure 4B). The non-tumorous liver revealed 
sinusoidal obstruction syndrome related to preoperative 
chemoradiation therapy and diffusely dysplastic change 
due to chronic HBV. There were no complications in 
the postoperative course, and the patient was discharged on 
postoperative day 29. As of March 2013, he had survived 
for more than 11 months after OLT without evidence of 
HCC recurrence.
Discussion
HCC is the fifth-commonest cancer globally and is diagnosed 
in more than 550,000 people worldwide each year.12 In South 
Korea, the incidence of HCC is increasing.13 Although active 
surveillance programs for early detection of HCC in patients 
with chronic liver disease have increased the proportion of 
early HCC patients,14 a considerable number of patients 
remain at high risk of diagnosis with advanced HCC at first 
presentation. If HCC is detected in its early stage, surgical 
resection, liver transplantation, and ablative locoregional 
therapies can be performed with a curative aim.
Among these treatment options, OLT is an attractive 
therapeutic modality, because the tumor and diseased cir-
rhotic liver can be cured simultaneously. Mazzaferro et al first 
defined a subgroup of patients with unresectable HCC for 
whom liver transplantation was appropriate; these definitions 
are now referred to as the Milan criteria.1, More recently, a 
considerable number of suggestions have been proposed in 
terms of expansion of traditional transplant criteria in several 
specialized centers; these expansions include the UCSF,2 
up-to-7,3 Tokyo,15 Kyoto,16 and Kyushu University criteria.17 
Meanwhile, downstaging through neoadjuvant locoregional 
therapy including transarterial chemoembolization (TACE), 
radiofrequency ablation (RFA), and selective radioemboliza-
tion with yttrium-90 labeled microspheres have also been 
recently attempted in patients who were initially beyond the 
Milan criteria.18 Chapman et al reported that selected patients 
with stages III/IV HCC could be downstaged to the Milan 
criteria with TACE in about one-fourth of cases with favor-
able midterm disease-free and overall survival rates, similar 
to stage II HCC.19 In addition, the combined approach of 
TACE plus either RFA or radioembolization has been known 
CCRT
10 cycles of HAIC every 4 weeks
5-FU (500 mg/day) (1st and 5th weeks) + RT (50 gray/20 fractions/5 weeks)
2009.10.26–2009.11.20
5-FU (500 mg/m2 x 3 days) + cisplatin (60 mg/m2 on day 2)
2009.12.22–2010.12.20
OLT
2012.4.19
Sorafenib
2010.5.4–2012.3.20
Figure 2 Scheme of therapy protocol. After CCRT with subsequent combined use of HAIC and sorafenib, the patient underwent OLT.
Abbreviations: HAIC, hepatic arterial infusion chemotherapy; 5-FU, 5-fluorouracil; RT, radiotherapy; CCRT, concurrent chemoradiation therapy; OLT, orthotopic liver 
transplantation.
Figure 3 Computed tomography scan before orthotopic liver transplantation 
demonstrated a decrease of the primary tumor to 6.4 cm with a large amount of 
ascites (A). A remarkable decrease in fluorodeoxyglucose uptake in the primary 
tumor was identified without visible distant metastasis on positron emission 
tomography and computed tomography (B).
Figure 4 Macroscopic aspect and microscopic examination of liver specimen. 
Grossly, the liver showed macronodular cirrhotic change and a yellow necrotic 
mass (6.3 × 5.6 cm) at segment 4/8 (A). Microscopic examination showed complete 
necrosis of the hepatocellular carcinoma (B, hematoxylin and eosin, 100×).
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to successfully downstage HCC in ∼60% of cases, which 
is higher than with either monotherapy.20,21 More recently, 
sorafenib has also been suggested for downstaging as a 
bridging or neoadjuvant therapy in selected patients with 
advanced HCC by slowing or halting tumor progression, 
especially when combined with locoregional therapies.22
Similar to previous studies of TACE, RFA, or yttrium-90 
as locoregional treatment modalities to downstage HCC,19,23 
we also tried to downstage HCC in our case using CCRT 
followed by the combined use of sorafenib and HAIC. CCRT 
and HAIC are used frequently in Asian countries, including 
South Korea and Japan.24 In a recent pilot study, CCRT 
showed excellent tumor response, with a median survival 
of 13.1 months and a 3-year overall survival rate of 24.1% 
in locally advanced tumors.8 In other studies conducted in 
South Korea and Japan, the efficacy and safety of repeated 
HAIC have also been reported with a median time to disease 
progression and overall survival of 4.1 to 7.0 months and 12.0 
to 15.9 months, respectively.25,26 We also added sorafenib 
when a new HCC lesion appeared during the repeated HAIC 
to overcome the development of potential resistance to 
repeated HAIC and to prevent distant metastasis. To date, 
several reports have supported the rationale of combining 
sorafenib with locoregional treatments, especially when the 
patient is refractory to TACE or develops TACE failure.27,28 
In addition, in a case report, sorafenib combined with 
HAIC showed significant tumor regression in patients with 
advanced HCC and portal vein thrombosis.29
Although we cannot clearly distinguish all therapeutic 
effects of CCRT, repeated HAIC, and sorafenib, the present 
case is the first report of OLT being performed via successful 
down-staging through a combination of locoregional treat-
ment modalities and a systemic target agent in a patient who 
was initially beyond the Milan or other extended criteria. In 
this case, there were no significant complications, with the 
exception of a mild degree of hand–foot syndrome related to 
sorafenib, during the entire treatment period. This suggests 
that the combination of sorafenib and locoregional treatment 
is safe and effective in terms of down-staging of HCC in select 
patients with advanced HCC. However, the appropriateness of 
this combined anti-cancer treatment strategy should be further 
investigated in a randomized large-scale study.
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